{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:23:54Z","timestamp":1792106634537,"version":"4.4.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Encouraging response has been achieved in relapsed\/refractory (R\/R) B-cell lymphoma treated by chimeric antigen receptor T (CAR-T) cells. The efficacy and safety of CAR-T cells in central nervous system lymphoma (CNSL) are still elusive. Here, we retrospectively analyzed 15 patients with R\/R secondary CNSL receiving CD19-specific CAR-T cell-based therapy. The patients were infused with CD19, CD19\/CD20 or CD19\/CD22 CAR-T cells following a conditioning regimen of cyclophosphamide and fludarabine. The overall response rate was 73.3% (11\/15), including 9 (60%) with complete remission (CR) and 2 (13.3%) with partial remission (PR). During a median follow-up of 12 months, the median progression-free survival (PFS) was 4 months, and the median overall survival (OS) was 9 months. Of 12 patients with systemic tumor infiltration, 7 (58.3%) achieved CR in CNS, and 5 (41.7%) achieved CR both systemically and in CNS. Median DOR for CNS and systemic disease were 8 and 4 months, respectively. At the end point of observation, of the 7 patients achieved CNS disease CR, one was still alive with sustained CR of CNS disease and systemic disease. The other 6 died of systemic progression. Of the 15 patients, 11 (73.3%) experienced grades 1-2 CRS, and no patient had grades 3-4 CRS. Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 3 (20%) patients, including 1 (6.6%) with grade 4 ICANS. All the CRS or ICANS were manageable. The CD19-specific CAR-T cell-based therapy appeared to be a promising therapeutic approach in secondary CNSL, based on its antitumor effects and an acceptable side effect profile, meanwhile more strategies are needed to maintain the response.<\/jats:p>","DOI":"10.3389\/fimmu.2022.965224","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T06:37:03Z","timestamp":1660891023000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Huanxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiling","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuekun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hujun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000449","article-title":"Central nervous system lymphoma: Approach to diagnosis and treatment","volume":"26","author":"Correia","year":"2020","journal-title":"Cancer J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.hoc.2019.03.008","article-title":"Central nervous system lymphoma","volume":"33","author":"Chukwueke","year":"2019","journal-title":"Hematol\/Oncol Clinics North America"},{"key":"B3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2018.01.073","article-title":"Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large b-cell lymphoma","volume":"93","author":"El-Galaly","year":"2018","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30174-6","article-title":"Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the international extranodal lymphoma study group-32 phase 2 trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/hon.2342","article-title":"Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and r-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study","volume":"35","author":"Doorduijn","year":"2017","journal-title":"Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000517531","article-title":"Outcome of a real-world patient cohort with secondary CNS lymphoma treated with high-intensity chemoimmunotherapy and autologous stem cell transplantation","volume":"44","author":"Thiele","year":"2021","journal-title":"Oncol Res Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large b-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large b-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse Large b-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse Large-B-Cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"New Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01306","article-title":"CAR T-cell therapy is effective but not long-lasting in b-cell lymphoma of the brain","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01099-4","article-title":"Axicabtagene ciloleucel CAR T-cell therapy for relapsed\/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies","volume":"56","author":"Ghafouri","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005292","article-title":"CAR T-cell therapy for secondary CNS DLBCL","volume":"5","author":"Ahmed","year":"2021","journal-title":"Blood Adv"},{"key":"B17","volume-title":"World health organization classificationof tumours of the haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large b cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0675","article-title":"CD19\/CD22 dual-targeted CAR T-cell therapy for Relapsed\/Refractory aggressive b-cell lymphoma: A safety and efficacy study","volume":"9","author":"Wei","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.14735\/amko2016295","article-title":"[Staging and treatment response evaluation in malignant lymphomas - Czech lymphoma study group recommendations according to criteria revised in 2014 (Lugano classification)]","volume":"29","author":"Sykorova","year":"2016","journal-title":"Klin Onkol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B24","unstructured":"2020 June 14. US department of health and human servicesNational cancer institute common terminology criteria for adverse events (CTCAE) version 4.03"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2017.09.002","article-title":"Cytokine release syndrome: Who is at risk and how to treat","volume":"30","author":"Frey","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.077917","article-title":"Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas","volume":"98","author":"Korfel","year":"2013","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012932","article-title":"CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network","volume":"139","author":"Alcantara","year":"2022","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41408-021-00523-2","article-title":"Sequential CD19\/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma","volume":"11","author":"Wu","year":"2021","journal-title":"Blood Cancer J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31646","article-title":"Double hit and double expressors in lymphoma: Definition and treatment","volume":"124","author":"Riedell","year":"2018","journal-title":"Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2378","article-title":"Double-hit signature with TP53 abnormalities predicts poor survival in patients with germinal center type diffuse Large b-cell lymphoma treated with r-CHOP","volume":"27","author":"Song","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1115940","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells","volume":"5","author":"Otahal","year":"2016","journal-title":"Oncoimmunology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01286-0","article-title":"BTK inhibitors and CAR T-cell therapy in treating mantle cell lymphoma-finding a dancing partner","author":"Munoz","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30461-9","article-title":"Enhancing CAR T-cell therapy through cellular imaging and radiotherapy","volume":"20","author":"Minn","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.965224\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T06:37:08Z","timestamp":1660891028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.965224\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2022.965224"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.965224","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"article-number":"965224"}}